Michael Szarek

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 31

Top Topics

Monoclonal Antibody

Acute Coronary Syndrome

Antiplatelet Therapy

Top Venues

Journal of the American Heart Association

Clinical journal of the American Society of Nephrology : CJASN

European journal of preventive cardiology

European heart journal. Cardiovascular pharmacotherapy

This page only lists publications with an associated author ORCID identifier.

Publications

Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association (2024)
Vikas Srinivasan Sridhar, Deepak L Bhatt, Ayodele Odutayo, Michael Szarek, Michael J Davies, Phillip Banks, Bertram Pitt, Ph Gabriel Steg, David Z I Cherney
Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial. Clinical journal of the American Society of Nephrology : CJASN 19 (5) (2024)
Michael Szarek, Esther Reijnders, Ph Gabriel Steg, J Wouter Jukema, Markus Schwertfeger, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Sergio Fazio, Genevieve Garon, Shaun G Goodman, Robert A Harrington, Harvey D White, Andreas M Zeiher, Christa Cobbaert, Gregory G Schwartz
Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES. European journal of preventive cardiology (2024)
Shaun G Goodman, Philippe Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Robert A Harrington, Johan Wouter Jukema, Harvey D White, Andreas M Zeiher, Garen Manvelian, Robert Pordy, Yann Poulouin, Wanda Stipek, Genevieve Garon, Gregory G Schwartz, null null
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Vikas Srinivasan Sridhar, Deepak L Bhatt, Ayodele Odutayo, Michael Szarek, Michael J Davies, Phillip Banks, Bertram Pitt, Ph Gabriel Steg, David Z I Cherney
Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in T2DM and CKD: A Secondary Analysis of the SCORED Trial. Clinical journal of the American Society of Nephrology : CJASN (2024)
Vikas Srinivasan Sridhar, Deepak L Bhatt, Ayodele Odutayo, Michael Szarek, Michael J Davies, Phillip Banks, Bertram Pitt, Ph Gabriel Steg, David Z I Cherney
Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial. Clinical journal of the American Society of Nephrology : CJASN 19 (5) (2024)
Vikas Srinivasan Sridhar, Deepak L Bhatt, Ayodele Odutayo, Michael Szarek, Michael J Davies, Phillip Banks, Bertram Pitt, Ph Gabriel Steg, David Z I Cherney
Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial. Clinical journal of the American Society of Nephrology : CJASN 19 (5) (2024)
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association 13 (8) (2024)
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association 13 (8) (2024)
Shaun G Goodman, Philippe Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Robert A Harrington, Johan Wouter Jukema, Harvey D White, Andreas M Zeiher, Garen Manvelian, Robert Pordy, Yann Poulouin, Wanda Stipek, Genevieve Garon, Gregory G Schwartz, null null
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association 13 (8) (2024)
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association 13 (8) (2024)
Zhong Yuan, Bennett Levitan, Hsiaowei Deng, Michael Szarek, Rupert M Bauersachs, Scott D Berkowitz, Lloyd P Haskell, Elliot S Barnathan, Marc P Bonaca
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association 13 (8) (2024)
Vikas Srinivasan Sridhar, Deepak L Bhatt, Ayodele Odutayo, Michael Szarek, Michael J Davies, Phillip Banks, Bertram Pitt, Ph Gabriel Steg, David Z I Cherney
Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial. Clinical journal of the American Society of Nephrology : CJASN 19 (5) (2024)
Michael Szarek, Esther Reijnders, Ph Gabriel Steg, J Wouter Jukema, Markus Schwertfeger, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Sergio Fazio, Genevieve Garon, Shaun G Goodman, Robert A Harrington, Harvey D White, Andreas M Zeiher, Christa Cobbaert, Gregory G Schwartz
Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES. European journal of preventive cardiology 31 (10) (2024)
Vikas Srinivasan Sridhar, Deepak L Bhatt, Ayodele Odutayo, Michael Szarek, Michael J Davies, Phillip Banks, Bertram Pitt, Ph Gabriel Steg, David Z I Cherney
Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial. Clinical journal of the American Society of Nephrology : CJASN 19 (5) (2024)
Shaun G Goodman, Philippe Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Robert A Harrington, Johan Wouter Jukema, Harvey D White, Andreas M Zeiher, Garen Manvelian, Robert Pordy, Yann Poulouin, Wanda Stipek, Genevieve Garon, Gregory G Schwartz
Safety Of The Pcsk9 Inhibitor Alirocumab: insights From 47,296 Patient-Years Of Observation. European heart journal. Cardiovascular pharmacotherapy (2024)
Shaun G Goodman, Philippe Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Robert A Harrington, Johan Wouter Jukema, Harvey D White, Andreas M Zeiher, Garen Manvelian, Robert Pordy, Yann Poulouin, Wanda Stipek, Genevieve Garon, Gregory G Schwartz, null null
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation. European heart journal. Cardiovascular pharmacotherapy 10 (4) (2024)
Michael Szarek, Esther Reijnders, Johan Wouter Jukema, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Sergio Fazio, Genevieve Garon, Shaun G Goodman, Robert A Harrington, L Renee Ruhaak, Markus Schwertfeger, Sotirios Tsimikas, Harvey D White, Phillippe Gabriel Steg, Christa M Cobbaert, Gregory G Schwartz, null null
Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of Three Tests. Circulation (2023)
Shaun G Goodman, Phillippe Gabriel Steg, Yann Poulouin, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Genevieve Garon, Robert A Harrington, Johan Wouter Jukema, Garen Manvelian, Wanda Stipek, Michael Szarek, Harvey D White, Gregory G Schwartz, null null
Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial. Journal of the American Heart Association (2023)
Gregory G Schwartz, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Maja Bujas-Bobanovic, Rafael Diaz, Sergio Fazio, Zlatko Fras, Shaun G Goodman, Robert A Harrington, Johan Wouter Jukema, Garen Manvelian, Robert Pordy, Kausik K Ray, Michel Scemama, Harvey D White, Ph Gabriel Steg, null null
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial. European heart journal (2023)
Connie N Hess, Judith Hsia, Ian A Carroll, Mark R Nehler, Wolfram Ruf, David A Morrow, Jose Carlos Nicolau, Otavio Berwanger, Michael Szarek, Warren H Capell, Shilpa Johri, Michael S Pursley, Ryan Gupta, Patrick S Meehan, Francesco Franchi, Mark B Effron, Debra Marshall, Christopher A Graybill, Sophie P Graybill, Thomas Keuer, Michael R Bristow, Marc P Bonaca
Novel Tissue Factor Inhibition for Thromboprophylaxis in COVID-19: Primary Results of the ASPEN-COVID-19 Trial. Arteriosclerosis, thrombosis, and vascular biology (2023)
Ulf Landmesser, Jennifer McGinniss, Ph Gabriel Steg, Deepak L Bhatt, Vera A Bittner, Rafael Diaz, Mirza Dilic, Shaun G Goodman, J Wouter Jukema, Megan Loy, Ivan Pećin, Robert Pordy, Steen H Poulsen, Michael Szarek, Harvey D White, Gregory G Schwartz, null null
Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab. European journal of preventive cardiology 29 (14) (2022)
Harvey D White, Gregory G Schwartz, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Chern-En Chiang, Rafael Diaz, Shaun G Goodman, Johan Wouter Jukema, Megan Loy, Neha Pagidipati, Robert Pordy, Arsen D Ristić, Andreas M Zeiher, Daniel M Wojdyla, Phillippe Gabriel Steg, null null
Alirocumab after acute coronary syndrome in patients with a history of heart failure. European heart journal 43 (16) (2022)
Scott D Berkowitz, Rupert M Bauersachs, Michael Szarek, Mark R Nehler, Eike Sebastian Debus, Manesh R Patel, Sonia S Anand, Warren H Capell, Connie N Hess, Judith Hsia, Nicholas J Leeper, David De Padua Brasil, Lajos Mátyás, Rafael Diaz, Marianne Brodmann, Eva Muehlhofer, Lloyd P Haskell, Marc P Bonaca
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. Journal of thrombosis and haemostasis : JTH 20 (5) (2022)
Emil Hagström, Phillippe Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Tabassome Simon, Rafael Diaz, Shaun G Goodman, Robert A Harrington, Johan Wouter Jukema, Evangelos N Liberopoulos, Nikolaus Marx, Jennifer McGinniss, Garen Manvelian, Robert Pordy, Michel Scemama, Harvey D White, Andreas M Zeiher, Gregory G Schwartz, null null
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. Circulation 146 (9) (2022)
Michael Szarek, Connie Hess, Manesh R Patel, W Schuyler Jones, Jeffrey S Berger, Iris Baumgartner, Brian Katona, Kenneth W Mahaffey, Lars Norgren, Juuso Blomster, Frank W Rockhold, Judith Hsia, F Gerry R Fowkes, Marc P Bonaca
Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. Journal of the American Heart Association 11 (11) (2022)
William A Murphy, Nan Lin, Amy Damask, Gregory G Schwartz, Phillippe Gabriel Steg, Michael Szarek, Poulabi Banerjee, Sergio Fazio, Garen Manvelian, Robert Pordy, Alan R Shuldiner, Charles Paulding
Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial. Circulation. Genomic and precision medicine 15 (3) (2022)
Michael Szarek, Deepak L Bhatt, Ph Gabriel Steg, Christopher P Cannon, Lawrence Alan Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra, Lars H Lund, Michel Komajda, Jeffrey M Testani, Christopher S Wilcox, Piotr Ponikowski, Renato Deláscio Lopes, Phillip Banks, Eshetu Tesfaye, Justin A Ezekowitz, Subodh Verma, Bertram Pitt, null null
Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. Annals of internal medicine 174 (8) (2021)
Sonia S Anand, Will Hiatt, Leanne Dyal, Rupert M Bauersachs, Scott D Berkowitz, Kelley R H Branch, Sebastian Debus, Keith A A Fox, Yan Liang, Eva Muehlhofer, Mark R Nehler, Lloyd P Haskell, Manesh Patel, Michael Szarek, Salim Yusuf, John William Eikelboom, Marc P Bonaca
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. European journal of preventive cardiology (2021)
Mori J Krantz, Sebastian E Debus, Judith Hsia, Manesh R Patel, Sonia S Anand, Mark R Nehler, Connie N Hess, Warren H Capell, Taylor Bracken, Michael Szarek, Lajos Mátyás, Dainis K Krievins, Patrice Nault, Stefan Stefanov, Lloyd P Haskell, Scott D Berkowitz, Eva Muehlhofer, William R Hiatt, Rupert M Bauersachs, Marc P Bonaca
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. European heart journal 42 (39) (2021)